Form 4: Merck Executive Betty Larson Reports Stock Option and Restricted Stock Unit Grants

EVP and Chief HR Officer of Merck & Co., Betty Larson, reports the acquisition of stock options and restricted stock units.

Summary

• Betty Larson, EVP and Chief HR Officer at Merck & Co., Inc., filed a Form 4 on May 02, 2024, reporting transactions related to stock options and restricted stock units.
• On April 30, 2024, Larson acquired 58,594 stock options with an exercise price of $129.22, vesting in three equal installments starting April 30, 2025, and expiring on April 29, 2034.
• Additionally, Larson acquired 31,055 stock options with the same terms as above.
• Larson also acquired 34,050 restricted stock units, which will vest in three equal installments starting April 30, 2025, and be distributed as shares of Merck & Co., Inc. common stock.
• Following these transactions, Larson directly owns 58,594 + 31,055 stock options and 34,050 restricted stock units.
• A Power of Attorney was executed on March 14, 2024, authorizing Jennifer Zachary, Jon Filderman, Kelly Grez, and Anthony Wildasin to act on Larson's behalf for Section 16 filings.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation matter, which is generally viewed neutrally to positively as it aligns executive interests with shareholder value.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.

Industry Context

Stock option and restricted stock unit grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in large pharmaceutical companies like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV).
• The vesting schedules, typically three to four years, are also consistent with industry norms.
• The size of the grant is likely determined by a number of factors including the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the stock option and restricted stock unit grants as a way to incentivize management performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates